BND-35 is a human monoclonal antibody (mAb) that targets LILRB4/ILT3/CD85k. It interferes with the interaction between ILT3 and APOE as well as fibronectin, thereby enhancing the pro-inflammatory activity of various myeloid cells and reversing T cell immunosuppression mediated by different inhibitory myeloid cells. BND-35 exhibits antitumor activity in hILT3 transgenic mouse tumor models.
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
